As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, Medicare director Meena Seshamani, and FDA Center for Drug Evaluation and Research director Patrizia Cavazzoni have retired or intend to retire prior to Trump's inauguration on Jan. 20.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.

Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current transition team, has died at 65. | Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current transition team,

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), has selected 15 additional drugs for pr

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce prescription drug costs.

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but expensive weight-loss drugs.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

The Biden Administration announced the next batch of 15 prescription drugs that will be included in price negotiations with companies — with the aim of lowering costs for people covered by Medicare.

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the second round of the program Jan. 17.

The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, cancers, and various other conditions were among the 15 drugs the Biden administration selected for the next round of Medicare price negotiation.